Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms.
Aging
Animals
Congresses as Topic
DNA Mutational Analysis
Humans
Inflammation
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/ therapy
Mastocytosis
/ therapy
Medical Oncology
/ methods
Mice
Mutation
Myeloproliferative Disorders
/ therapy
Prognosis
Societies, Medical
Staurosporine
/ analogs & derivatives
Translational Research, Biomedical
/ methods
United States
IFNα
MPNs
clonal heterogeneity
inflammaging
investigational therapies
Journal
Hematological oncology
ISSN: 1099-1069
Titre abrégé: Hematol Oncol
Pays: England
ID NLM: 8307268
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
12
04
2019
accepted:
13
04
2019
pubmed:
24
4
2019
medline:
10
9
2019
entrez:
24
4
2019
Statut:
ppublish
Résumé
The 60th American Society of Hematology (ASH) held in San Diego in December 2018 was followed by the 13th Post-ASH chronic myeloproliferative neoplasms (MPNs) workshop on December 4 and 5, 2018. This closed annual workshop, first introduced in 2006 by Goldman and Mughal, was organized in collaboration with Alpine Oncology Foundation and allowed experts in preclinical and clinical research in the chronic MPNs to discuss the current scenario, including relevant presentations at ASH, and address pivotal open questions that impact translational research and clinical management. This review is based on the presentations and deliberations at this workshop, and rather than provide a resume of the proceedings, we have selected some of the important translational science and treatment issues that require clarity. We discuss the experimental and observational evidence to support the intimate interaction between aging, inflammation, and clonal evolution of MPNs, the clinical impact of the unfolding mutational landscape on the emerging targets and treatment of MPNs, new methods to detect clonal heterogeneity, the challenges in managing childhood and adolescent MPN, and reflect on the treatment of systemic mastocytosis (SM) following the licensing of midostaurin.
Substances chimiques
Staurosporine
H88EPA0A3N
midostaurin
ID912S5VON
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
240-252Subventions
Organisme : Unrestricted educational grants from Incyte, Novartis, Pharma Essentia and Alpine Oncology Foundation
Informations de copyright
© 2019 John Wiley & Sons, Ltd.
Références
Mughal TI, Radich JP, Deininger MW, et al. Chronic myeloid leukemia: reminiscences and dreams. Haematologica. 2016;101(5):541-558.
Srour SA, Devesa SS, Morton LM, et al. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12. Br J Haematol. 2016;174(3):382-396.
Deininger MWN, Tyner JW, Solary E. Turning the tide in myelodysplastic/myeloproliferative neoplasms. Nat Rev Cancer. 2017;17(7):425-440.
Fulop T, Witkowski JM, Olivieri F, Larbi A. The integration of inflammaging in age-related diseases. Semin Immunol. 2018;40:17-35.
Elias HK, Bryder D, Park CY. Molecular mechanisms underlying lineage bias in aging hematopoiesis. Semin Hematol. 2017;54(1):4-11.
Chambers SM, Shaw CA, Gatza C, Fisk CJ, Donehower LA, Goodell MA. Aging hematopoietic stem cells decline in function and exhibit epigenetic dysregulation. PLoS Biol. 2007;5(8):e201.
Beerman I, Bhattacharya D, Zandi S, et al. Functionally distinct hematopoietic stem cells modulate hematopoietic lineage potential during aging by a mechanism of clonal expansion. Proc Natl Acad Sci USA. 2010;107(12):5465-5470.
Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet. 2012;44(11):1179-1181.
Genovese G, Kahler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477-2487.
McKerrell T, Park N, Moreno T, et al. Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. Cell Rep. 2015;10(8):1239-1245.
Xie M, Lu C, Wang J, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014;20(12):1472-1478.
Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488-2498.
Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126(1):9-16.
Young AL, Challen GA, Birmann BM, Druley TE. Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat Communications. 2016;7(1):12484.
Cai Z, Kotzin JJ, Ramdas B, et al. Inhibition of inflammatory signaling in Tet2 mutant preleukemic cells mitigates stress-induced abnormalities and clonal hematopoiesis. Cell Stem Cell. 2018;23(6):833-849 e5.
Abegunde SO, Buckstein R, Wells RA, Rauh MJ. An inflammatory environment containing TNFalpha favors Tet2-mutant clonal hematopoiesis. Exp Hematol. 2018;59:60-65.
Fleischman AG, Aichberger KJ, Luty SB, et al. TNFalpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood. 2011;118(24):6392-6398.
Meisel M, Hinterleitner R, Pacis A, et al. Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature. 2018;557(7706):580-584.
Kristinsson SY, Bjorkholm M, Hultcrantz M, Derolf ÅR, Landgren O, Goldin LR. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol. 2011;29(21):2897-2903.
Agathocleous M, Meacham CE, Burgess RJ, et al. Ascorbate regulates haematopoietic stem cell function and leukaemogenesis. Nature. 2017;549(7673):476-481.
Fuster JJ, MacLauchlan S, Zuriaga MA, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017;355(6327):842-847.
Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377(2):111-121.
Dorsheimer L, Assmus B, Rasper T, et al. Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure. JAMA Cardiol. 2019;4(1):25-33.
Valent P, Bonnet D, De Maria R, et al. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer. 2012;12(11):767-775.
Valent P, Bonnet D, Wöhrer S, et al. Heterogeneity of neoplastic stem cells: theoretical, functional, and clinical implications. Cancer Res. 2013;73(3):1037-1045.
Klco JM, Miller CA, Griffith M, et al. Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. JAMA. 2015;314(8):811-822.
Paguirigan AL, Smith J, Meshinchi S, Carroll M, Maley C, Radich JP. Single-cell genotyping demonstrates complex clonal diversity in acute myeloid leukemia. Science Translational Medicine. 2015;7:281-286.
Schmitt MW, Kennedy SR, Salk JJ, Fox EJ, Hiatt JB, Loeb LA. A Detection of ultra-rare mutations by next-generation sequencing. Proc Natl Acad Sci USA. 2012;109(36):14508-14513.
Schmitt MW, Fox EJ, Prindle MJ, et al. Sequencing of small genomic targets with high efficiency and extreme accuracy. Nature Methods. 2015;12(5):423-425.
Warfvinge R, Ulfsson LG, Sommarin NE, et al. Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML. Blood. 2017;129(17):2384-2394.
Zheng GXY, Terry JM, Belgrader P, et al. Massively parallel digital transcriptional profiling of single cells. Nature Comm. 2017;8:14049.
Bethan P, Mead A. Single-cell approaches reveal novel cellular pathways for megakaryocyte and erythroid differentiation. Blood. 2019;133(13):1427-1435. https://doi.org/10.1182/blood-2018-11-835371
Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood. 2011;117(18):4706-4715.
Kiladjian JJ, Giraudier S, Cassinat B. Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone. Leukemia. 2016;30(4):776-781.
Mullally A, Bruedigam C, Poveromo L, et al. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera. Blood. 2013;121(18):3692-3702.
Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112(8):3065-3072.
Masarova L, Patel KP, Newberry KJ, et al. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. Lancet Haematol. 2017, 4(4):e165-e175.
Gisslinger H, Klade C, Georgiev P, et al. Evidence for superior efficacy and disease modification after three years of prospective randomized controlled treatment of polycythemia vera patients with ropeginterferon alfa-2b vs. HU/BAT. Blood. 2018;132:579.
Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, et al. Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015;126(15):1762-1769.
Kiladjian JJ, Soret-Dulphy J, Resche-Rigon M, et al. Ruxopeg, a multi-center Bayesian Phase 1/2 adaptive randomized trial of the combination of ruxolitinib and pegylated interferon alfa 2a in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis. Blood. 2018;32:581.
Maslah N, Dagher T, Edmond V, et al. Specific and synergistic targeting of JAKV617F cells by interferon alpha and arsenic. Blood. 2018;132:52.
Hobbs GS, Rozelle S, Mullally A. The development and use of janus kinase 2 inhibitors for the treatment of myeloproliferative neoplasms. Hematol Oncol Clin North Am. 2016;31:613-626.
Quintás-Cardama A, Abdel-Wahab O, Manshouri T, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood. 2013;122(6):893-901.
Hasan S, Lacout C, Marty C, et al. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNa. Blood. 2013;122(8):1464-1477.
Kjaer L, Cordua S, Holmström MO, et al. Differential dynamics of CALR mutant allele burden in myeloproliferative neoplasms during interferon alfa treatment. PLoS One. 2016;11. https://doi.org/10.1371/journal.pone.0165336(10):e0165336
Cassinat B, Verger E, Kiladjian J-J. Interferon alfa therapy in CALR-mutated essential thrombocythemia. N Engl J Med. 2014;371:188-189.
Verger E, Cassinat B, Chauveau A, et al. Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations. Blood. 2015;126(24):2585-2591.
Ianotto JC, Chauveau A, Boyer-Perrard F, et al. Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of myeloproliferative neoplasms (FIM) study. Haematologica. 2018;103(3):438-446.
Czech J, Cordua S, Weinbergerova B, et al. JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation. Leukemia. 2018;33(4):995-1010. https://doi.org/10.1038/s41375-018-0295-6
Mosca M, Lamrani L, Marzac C, et al. Differential impact of interferon alpha on JAK2V617F and calr mutated hematopoietic stem and progenitor cells in classical MPN. Blood. 2018;132:4333.
Bozkus CC, Roudko V, Finnigan JP, et al. Immune checkpoint blockade enhances calreticulin-induced T-cell immunity in myeloproloferative neoplasms. Cancer Immunol Res. 2019;7(suppl 2). abs nr B072
Gotlib J. KIT Mutations in mastocytosis and their potential as therapeutic targets. Immunology & Allergy Clinics. 2006;26:575-592.
Gotlib J, DeAngelo D, George TI, et al. KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: report of a fully accrued Phase II trial. Blood. 2010;116:316.
Arock M, Sotlar K, Akin C, et al. KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocyctosis. Leukemia. 2015;29(6):1223-1232.
Hartmann K, Escribano L, Grattan C, et al. Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocyctosis; the American Academy of Allergy, Athma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy & Clin Imm. 2016;137(1):35-45.
Krauth MT, Mirkina I, Hermann H, Baumgartner C, Kneidinger M, Valent P. Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells. Clin Exp Allergy. 2009;39(11):1711-1720.
Peter B, Winter GE, Blatt K, et al. Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth. Leukemia. 2016;30(2):464-472.
Valent P, Akin C, Hartmann K, et al. Midostaurin: a magic bullet that blocks mast cell expansion and activation. Ann Oncol. 2017;28(10):2367-2376.
Baird JH, Gotlib J. Clinical validation of KIT inhibition in advanced ststemic mastocytosis. Curr Hematol Malignancy Rep. 2018;13(5):407-416.
Dieninger MW, Gotlib J, Robinson WA, et al. Avapritinib (BLU-285), a selective KIT inhibitor, is associated with high response rate and tolerable safety profile in advanced systemic mastocytosis: results of a phase 1 study. Blood. 2018;132:1132.
Gotlib J, Radia D, DeAngelo DJ, et al. Avapritinib, a potent and selective inhibitor of KITD816V, improves symptoms of advanced ststemic mastocytosis (AdvSM): analyses of patient reported outcomes (PROs) from the Phase 1 (EXPLORER) study using the (AdvSM) symptom assessment form (AdvSM-SAF), a new PRO questionnaire for (AdvSM). Blood. 2018;132:351.
Ustun C, Arock M, Kluin-Nelemans HC, et al. Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice. Haematologica. 2016;101(10):1133-1143.
Munoz-Gonzalez JI, Jara-Acevedo M, Alvarez-Twose I, et al. Impact of somatic and germline mutations on the outcome of systemic mastocytosis. Blood Advances. 2018;2(21):2814-2828. https://doi.org/10.1182/bloodadvances2018020628
Shomali W, Gotlib J. The new tool “KIT” in advanced systemic mastocytosis. Hematology. 2018;2018(1):127-136. https://doi.org/10.1182/asheducation-2018.1.127
Gotlib J, Gerds AT, Bose P, et al. Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Comprehensive Cancer Network. 2019;16(12):1500-1537. https://doi.org/10.6004/jnccn.2018.0088
Budnik J, Milan M. A registry-based analysis of survival outcomes in mast cell leukemia. Leuk Res. 2019;78:24-28.
Verstovsek S, Mesa RA, Gotlib J, et al. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017;10(1):55.
Harrison CN, Vannucchi AM, Kiladjian JJ, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30(8):1701-1707.
Kuykendall AT, Shah S, Talati C, et al. Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. Ann Hematol. 2018;97(3):435-441.
Harrison CN, Schaap N, Vannucchi AM, et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol. 2017;4(7):e317-e324.
Harrison C, Mesa M, Jamieson C, Hood BJ. Case series of potential Wernicke's encephalopathy in patients treated with Fedratinib. Blood. 2017;634:4197.
Gangat N, Phelps A, Lasho TL, et al. A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy. Blood Cancer Journal. 2019;9(2):11; https://doi.org/10.1038/s41408-018-0167
ASH Clinical News. Momelotinib Trial in Myelofibrosis Fails to Meet Primary Endpoint. 2018; https://www.ashclinicalnews.org/news/momelotinib-trial-myelofibrosis-fails-meet-primary-endpoint/. Accessed March 23rd 2018.
Mascarenhas J, Hoffman R, Talpaz M, et al. Pacritinib versus best available therapy, including Ruxolotinib, in patients with myelofibrosis. JAMA Oncol. 2018;4(5):652-659. https://doi.org/10.1001/jamaoncol.2017.5818
Pemmaraju N, Carter BZ, Kantarjian HM, et al. LCL161, an oral Smac mimetic/IAP antagonist for patients with myelofibrosis (MF): novel translational findings among long-term responders in a phase 2 clinical trial. Blood. 132:687.
Mascarenhas J, Komrokji R, Cavo M, et al. Imetelstat is effective treatment for patients with intermediate-2 or high-risk myelofibrosis who have relapsed on or are refractory to janus kinase inhibitor therapy: results of a phase 2 randomized study of two dose levels. Blood ASH. 2018;132:685.
Pemmaraju N, Gupta V, Schiller GJ, et al. Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate or high risk relapsed/refractory myelofibrosis. Blood. 2018;132:1773.
Frankel AE, Woo JH, Ahn C, et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014;124(3):385-392.
Verstovsek S, Hasserjian RP, Pozdnyakova O, et al. PRM-151 in myelofibrosis: efficacy and safety in an open label extension study. Blood. 2018;132:686.
Bose P, Daver N, Pemmaraju N, et al. Sotatercept (ACE-011) alone and in combination with ruxolitinib in patients (pts) with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) and anemia. Blood. 2017;130:255.
Fenaux P, Kiladjian JJ, Platzbecker U. Luspatercept for the treatment of anemia in myelodysplastic syndrome and primary myelofibrosis. Blood. 2019;133:790-794.
Rampal RK, Verstovsek S, Devlin SM, et al. Safety and efficacy of combined ruxoltinib and thalidomide in patients with myelofibrosis: initial results of a phase II study. Blood. 2018;132:354.
Masarova L, Verstovsek S, Hidalgo-Lopez JE, et al. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018;132(16):1664-1674.
Daver NG, Kremyanskaya M, O'Connell C, et al. A phase 2 study of the safety and efficacy of INCB050465, a selective PI3Kδ inhibitor, in combination with ruxolitinib in patients with myelofibrosis. Blood. 2018;132:353.
Vainchenker W, Leroy E, Gilles L, Marty C, Plo I, Constantinescu SN. JAK inhibitors for the treatment of myeloproliferative neoplasm and other disorders. F1000Res. 2018;7:82. https://doi.org/10.12688/f1000research.13167.1
Kleppe M, Koche R, Zou L, et al. Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms. Cancer Cell. 2018;33(1):29-43.e7.
Kremyanskaya M, Hoffman R, Mascarenhas J, et al. A phase 2 study of CPI-0610, a bromodomain and extraterminal (BET) inhibitor, in patients with myelofibrosis (MF). Blood. 2018;132:5481.
Nieborowska-Skorska M, Maifrede S, Dasgupta Y, et al. Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms. Blood. 2017 Dec 28;130(26):2848-2859.
McKenney AS, Lau AN, Somasundara AVH, et al. JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition. J Clin Invest. 2018;128(2):789-804.
Stivala S, Codilupi T, Brkic S, et al. Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms. J Clin Invest. 129(4):1596-1611. https://doi.org/10.1172/JCI98785
Sevin M, Kubovcakova L, Pernet N, et al. HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis. Nat Communications. 2019;9(1):1431. https://doi.org/10.1038/s41467-018-03627-9
Hofmann I. Myeloproliferative Neoplasms in Children. J Hematop. 2015;8(3):143-157.
Barbui T. How to manage children and young adults with myeloproliferative neoplasms. Leukemia. 2012;26(7):1452-1457.
Ianotto JC, Curto-Garcia N, Lauermannova M, Radia D, Kiladjian JJ, Harrison CN. Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age, a systematic review. Haematologica. 2019 Jan;24, epub ahead of print, https://doi.org/10.3324/haematol.2018.200832:haematol.2018.200832.
Giona F, Teofili L, Moleti ML, et al. Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome. Blood. 2012;119(10):2219-2227.
Kucine N, Chastain KM, Mahler MB, Bussel JB. Primary thrombocytosis in children. Haematologica. 2014;99(4):62-628.
Karow A, Nienhold R, Lundberg P, et al. Mutational profile of childhood myeloproliferative neoplasms. Leukemia. 2015;29(12):2407-2409.
Fu R, Liu D, Cao Z, et al. Distinct molecular abnormalities underlie unique clinical features of essential thrombocythemia in children. Leukemia. 2016;30(3):746-749.
Kucine N, Viny AD, Rampal R, et al. Genetic analysis of five children with essential thrombocytosis identified mutations in cancer-associated genes with roles in transcriptional regulation. Haematologica. 2016;101(6):e237-e239.
Kucine N, Al-Kawaaz M, Hajje D, et al. Difficulty distinguishing essential thrombocythaemia from polycythaemia vera in children with JAK2V617F-positive myeloproliferative neoplasms. Br J Haematol. 2018;185(1):136-139. https://doi.org/10.1111/bjh.15386
Fowles JS, How J, Allen JM, Oh SJ. Young versus old age at diagnosis confers genomic profiles in atients with polycythemia vera. Leukemia. 2019. https://doi.org/10.1038/s41375-018-0349-9
Rumi E, Cazzola M. Advances in understanding the pathogenesis of familial myeloproliferative neoplasms. Br J Haematol. 2017;178(5):689-698.
Kelly K, McMahon C, Langabeer S, Eliwan H, O'Marcaigh A, Smith OP. Congenital JAK2V617F polycythemia vera: where does the genotype-phenotype diversity end? Blood. 2008;112(10):4356-4357.
Mesa R, Jamieson C, Bhatia R, et al. NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. J Natl Compr Cancer Netw. 2017;15(10):1193-1207.